Abstract
The Special Programme of Research in Human Reproduction (HRP), co-sponsored by the UNDP, UNFPA, WHO, and the World Bank, is celebrating 40 years of activities with an expansion of its mandate and new co-sponsors. When it began, in 1972, the main focus was on evaluating the acceptability, effectiveness, and safety of existing fertility-regulating methods, as well as developing new, improved modalities for family planning. In 1994, HRP not only made major contributions to the Plan of Action of the International Conference on Population and Development (ICPD); it also broadened its scope of work to include other aspects of health dealing with sexuality and reproduction, adding a specific perspective on gender issues and human rights. In 2002, HRP’s mandate was once again broadened to include sexually transmitted infections and HIV/AIDS and in 2003 it was further expanded to research activities on preventing violence against women and its many dire health consequences. Today, the work of the Programme includes research on: the sexual and reproductive health of adolescents, women, and men; maternal and perinatal health; reproductive tract and sexually transmitted infections (including HIV/AIDS); family planning; infertility; unsafe abortion; sexual health; screening for cancer of the cervix in developing countries, and gender and reproductive rights. Additional activities by the Programme have included: fostering international cooperation in the field of human reproduction; the elaboration of WHO’s first Global Reproductive Health Strategy; work leading to the inclusion of ICPD’s goal ‘reproductive health for all by 2015’ into the Millennium Development Goal framework; the promotion of critical interagency statements on the public health, legal, and human rights implications of female genital mutilation and gender-biased sex selection. Finally, HRP has been involved in the creation of guidelines and tools, such as the ‘Medical eligibility criteria for contraceptive use’, the ‘Global handbook for family planning providers’, the ‘Definition of core competencies in primary health care’, and designing tools for operationalizing a human rights approach to sexual and reproductive health programmes.
References
1.
Kessler A: Establishment and early developments of the programme; in Khanna J, Van Look PFA, Griffin PD (eds): Reproductive Health: A Key to a Brighter Future – Biennial Report for 1990–1991 of the Special Programme of Research, Development, and Research Training in Human Reproduction. Geneva, WHO, 1992.
2.
World Health Organization, Regional Office for South-East Asia: Final report on pilot studies in family planning. New Delhi, WHO, 1954, vol I and II.
3.
Work of the Fifth World Health Assembly: population problems. Chron World Health Organ 1952;6:183–184.
4.
Litsios S: The Third Ten Years of the World Health Organization, 1968–1977. Geneva, WHO, 2008, pp 94–95.
5.
WHO Expanded Programme of Research, Development and Research Training in Human Reproduction: First annual report. Geneva, WHO, 1973.
6.
Diczfalusy E: World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction. The first fifteen years: a review. Contraception 1986;34:3–119.
7.
Fathalla MF: Reproductive health in the world: two decades of progress and the challenge ahead; in Khanna J, Van Look PFA, Griffin PD (eds): Reproductive Health: A Key to a Brighter Future – Biennial Report for 1990–1991 of the Special Programme of Research, Development, and Research Training in Human Reproduction. Geneva, WHO, 1992.
8.
Skakkebaek NE, Negro-Vilar A, Michal F, Fathalla MF: Impact of the environment on reproductive health: report and recommendations of a WHO international workshop. Danish Med Bull 1991;38:425–426.
9.
Gakidou E, Vayena E: Use of modern contraception by the poor is falling behind. PLoS Med 2007;4:e31.
10.
Gonzales R, Requejo JH, Nien JK, Merialdi M, Betran AP, Chile Maternal, Newborn and Child Writing Group: Tackling health inequities in Chile: maternal, newborn, and child mortality between 1990 and 2004. Am J Public Health 2009;99:1220–1226.
11.
United Nations, Department of Economic and Social Affairs, Population Division: World population prospects: the 2010 revision. New York, UN, 2011.
12.
United Nations Population Information Network (POPIN), UN Population Division, Department of Economic and Social Affairs, with support from the UN Population Fund (UNFPA): Report of the International Conference on Population and Development (Cairo, 5–13 September 1994). Document A/CONF.171/13: report of the ICPD (94/10/18). New York, UN, 1994.
13.
World Health Organization: Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets: global strategy adopted by the 57th World Health Assembly. Geneva, WHO, 2004, p 36.
14.
World Health Organization: Global strategy for the prevention and control of sexually transmitted infections: 2006–2015 – breaking the chain of transmission. Geneva, WHO, 2007, pp 61.
15.
United Nations: Report of the Secretary-General on the work of the Organization: official records of the General Assembly, sixty-first session, suppl 1 (A/61/1). New York, UN, 2006.
16.
Lawn JE, Cousens S, Zupan J, Lancet Neonatal Survival Steering Team: 4 million neonatal deaths: when? Where? Why? Lancet 2005;365:891–900.
17.
Ronsmans C, Graham WJ, Lancet Maternal Survival Series steering group: Maternal mortality: who, when, where, and why. Lancet 2006;368:1189–1200.
18.
Black RE, Morris SS, Bryce J: Where and why are 10 million children dying every year? Lancet 2003;361:2226–2234.
19.
Ban K: Global Strategy for Women’s and Children’s Health. http://www.who.int/pmnch/activities/jointactionplan/en/.
20.
UNAIDS, UNDP, UNECA, UNESCO, UNFPA, UNHCHR, UNHCR, UNICEF, UNIFEM, WHO: Eliminating female genital mutilation: an interagency statement. Geneva, WHO, 2008.
21.
UNFPA, UNHCR, UNICEF, UNIFEM, WHO, FIGO, ICN, MWIA, WCPA, WMA: Global strategy to stop health-care providers from performing female genital mutilation. Geneva, WHO, 2010.
22.
World Health Organization, Department of Reproductive Health and Research: Preventing gender-biased sex selection: an interagency statement – OHCHR, UNFPA, UNICEF, UN Women and WHO. Geneva, WHO, 2011.
23.
van der Poel SZ: Historical walk: the HRP Special Programme and infertility. Gynecol Obstet Invest 2012;74:218–227.
24.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17β, luteinizing hormone, follicle-stimulating hormone, and progesterone. 1. Probit analysis. Am J Obstet Gynecol 1980;138:383–389.
25.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: Temporal relationships between ovulation and defined changes in the concentration of plasma estradiol-17β, luteinizing hormone, follicle-stimulating hormone, and progesterone. 2. Histologic dating. Am J Obstet Gynecol 1981;139:886–895.
26.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: Temporal relationships between indices of the fertile period. Fertil Steril 1982;39:647–655.
27.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: A prospective multicentre trial of the ovulation method of natural family planning. 1. The teaching phase. Fertil Steril 1981;36:152–158.
28.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: A prospective multicentre trial of the ovulation method of natural family planning. 2. The effectiveness phase. Fertil Steril 1981;36:591–598.
29.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: A prospective multicentre trial of the ovulation method of natural family planning. 3. Characteristics of the menstrual cycle and of the fertile phase. Fertil Steril 1983;40:773–778.
30.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: A prospective multicentre trial of the ovulation method of natural family planning. 4. The outcome of pregnancy. Fertil Steril 1984;41:593–598.
31.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: The ovulation method of natural family planning. Bull World Health Organ 1985;63:44–46.
32.
Singh H, Saxena BB, Rathnam P: Clinical validation of enzyme-immunoassay of human luteinizing hormone (hLH) in the detection of the preovulatory luteinizing hormone (LH) surge in urine. Fertil Steril 1984;41:210–217.
33.
World Health Organization, Task Force on Methods for the Determination of the Fertile Period: The measurement of urinary steroid glucuronides as indices of the fertile period in women. J Steroid Biochem 1982;17:695–702.
34.
Schiphorst LE, Collins WP, Royston, JP: An estrogen test to determine the times of potential fertility in women. Fertil Steril 1985;44:328–334.
35.
Labbok M: Breastfeeding and contraception. N Engl J Med 1983;308:351.
36.
World Health Organization, Task Force on Methods for the Natural Regulation of Fertility: The World Health Organization multinational study of breast-feeding and lactational amenorrhea. 1. Description of infant feeding patterns and of the return of menses. Fertil Steril 1998;70:448–460.
37.
World Health Organization, Task Force on Methods for the Natural Regulation of Fertility: The World Health Organization multinational study of breast-feeding and lactational amenorrhea. 2. Factors associated with the length of amenorrhea. Fertil Steril 1998;70:461–471.
38.
World Health Organization, Task Force on Methods for the Natural Regulation of Fertility: The World Health Organization multinational study of breast-feeding and lactational amenorrhea. 3. Pregnancy during breast-feeding. Fertil Steril 1999;72:431–440.
39.
World Health Organization, Task Force on Methods for the Natural Regulation of Fertility: The World Health Organization multinational study of breast-feeding and lactational amenorrhea. 4. Postpartum bleeding and lochia in breast-feeding women. Fertil Steril 1999;72:441–447.
40.
Fajans P, Simmons R, Ghiron L: Helping public sector health systems innovate: the strategic approach to strengthening reproductive health policies and programs. Am J Public Health 2006;96:435–440.
41.
Benagiano G, Fraser I: The Depo-provera debate: commentary on the article ‘Depo-Provera, a critical analysis’. Contraception 1981;24:493–528.
42.
Finkel NC, Berliner VR: The extrapolation of experimental findings (animal to man): the dilemma of systematically administered contraceptives. International Academy of Pathology, 62nd Annual Meeting, Washington, 1973.
43.
World Health Organization: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 1. Use-effectiveness. Contraception 1977;15:513–533.
44.
World Health Organization: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects. Contraception 1978;17:395–406.
45.
World Health Organization: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate given in two dosage regimens and depot-medroxyprogesterone acetate – a preliminary report. Contraception 1982;25:1–11.
46.
World Health Organization: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate given in two dosage regimens and depot-medroxyprogesterone acetate – final report. Contraception 1983;28:1–20.
47.
World Health Organization: Facts about injectable contraceptives. Bull World Health Organ 1982;60:199–210.
48.
Kovács L, Resch BA (eds): Research on Human Reproduction: 25 Years of Achievement with the WHO Special Programme of Research, Development and Research Training in Human Reproduction – A Symposium to Celebrate the 25th Anniversary of WHO-HRP and Its Collaborating Centres, 13–14 October, 1997, Szeged, Hungary. Szeged, Albert Szent-Gyorgyi Medical University Press, 1998.
49.
Benagiano G, Diczfalusy E, Goldzieher JW, et al: Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 1. Use-effectiveness. Contraception 1977;15:513–533.
50.
Benagiano G, Diczfalusy E, Diethelm P, et al: Multinational comparative clinical evolution of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects. Contraception 1978;17:395–406.
51.
Crabbe P, Diczfalusy E, Djerassi C: Injectable contraceptive synthesis: an example of international cooperation. Science 1980;209:992–994.
52.
Crabbe P, Archer S, Benagiano G, Diczfalusy E, Djerassi C, Fried J, Higuchi T: Design of the WHO Chemical Synthesis Programme. Steroids 1983;41:243–254.
53.
Steroids 1983;41:242–425.
54.
World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction: Annual Technical Report 1996. Geneva, WHO, 1997, pp 41–43.
55.
World Health Organization, Department of Reproductive Health and Research: Biennial Technical Report 2005–2006. Geneva, WHO, 2007, pp 32–33.
56.
Garza-Flores J, Rodriguez V, Perez-Palacios G, et al: A multicentre pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. 1. Different doses of HRP112 and DepoProvera. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1987;36:441–457.
57.
Aedo AR, Landgren BM, Johannisson E, et al: Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparation. Contraception 1985;31:453–469.
58.
Fotherby K, Benagiano G, Toppoyada HK, et al: A preliminary pharmacological trial of the monthly injectable contraceptive, Cycloprovera. Contraception 1982;25:261–272.
59.
Comparative Study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on lipid and lipoprotein metabolism. United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1997;56:193–207.
60.
Comparative Study of the effects of two once-a-month injectable steroidal contraceptives (Mesigyna and Cyclofem) on glucose metabolism and liver function. United Nations Development Program/United Population Fund/World Health Organization/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1998;57:71–81.
61.
United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation: Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem and Mesigyna) and one oral contraceptive (Ortho-Novum 1/35) on coagulation and fibrinolysis. Contraception 2003;68:159–176.
62.
World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation: A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intra-muscular injection. 1. Contraceptive efficacy and side-effects. Contraception 1988;37:1–20.
63.
World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation: A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intra-muscular injection. 2. The comparison of bleeding patterns. Contraception 1989;40:531–551.
64.
Sang GW, Shao QX, Ge RS, et al: A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. Contraception 1995;51:167–183.
65.
Sang GW, Shao QX, Ge RS, et al: A multicentred phase III comparative clinical trial of Mesigyna, Cyclofem and Injectable No. 1 given monthly by intramuscular injection to Chinese women. 2. The comparison of bleeding patterns. Contraception 1995;51:185–192.
66.
Hassan EO, El-Nahal N, El-Hussein M: Acceptability of the once-a-month injectable contraceptives Cyclofem and Mesigyna in Egypt. Contraception 1994;40:469–88.
67.
Hassan EO, El-Nahal N, El-Hussein M: Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt: efficacy, causes of discontinuation, and side effects. Contraception 1999;60:87–92.
68.
Hall PE: The introduction of Cyclofem into national family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Task Force on Research on Introduction and Transfer of Technologies for Fertility Regulation, Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Contraception 1994;49:489–507.
69.
Simmons R, Fajans P, Lubis F: Contraceptive introduction and the management of choice: the role of Cyclofem in Indonesia. Contraception 1994;49:509–525.
70.
Facts about an implantable contraceptive: memorandum from a WHO Meeting. Bull World Health Org 1985;63:485–494.
71.
UNDP, UNFPA, WHO, World Bank, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-Acting Systemic Agents for Fertility Regulation: Study of the effects of the implantable contraceptive Norplant on lipid and lipoprotein metabolism. Contraception 1999;59:31–45.
72.
Massai R, Pavez M, Fuentealba B, Croxatto H, d’Arcangues C: Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004;70:47–54.
73.
d’Arcangues C, Piaggio G, Brache V, Aissa RB, Hazelden C, Massai R, Pinol A, Subakir SB, Su-juan G, Study Group on Progestogen-Induced Vaginal Bleeding Disturbances: Effectiveness and acceptability of vitamin E and low-dose aspirin, alone or in combination, on Norplant-induced prolonged bleeding. Contraception 2004;70:451–462.
74.
d’Arcangues C, Jackson E, Brache V, Piaggio G, Study Group on Progestogen-Induced Vaginal Bleeding Disturbances: Women’s views and experiences of their vaginal bleeding patterns: an international perspective from Norplant users. Eur J Contracept Reprod Health Care 2011;16:9–17.
75.
Thomas DB: The WHO Collaborative Study of Neoplasia and Steroid Contraceptives: the influence of combined oral contraceptives on risk of neoplasms in developing and developed countries. Contraception 1991;43:695–710.
76.
Epithelial ovarian cancer and combined oral contraceptives: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989;18:538–545.
77.
Endometrial cancer and combined oral contraceptives: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1988;17:263–269.
78.
Breast cancer and combined oral contraceptives: results from a multinational study – the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Br J Cancer, 1990;61:110–119.
79.
Invasive squamous-cell cervical carcinoma and combined oral contraceptives: results from a multinational study – the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1993;55:228–236.
80.
Thomas DB, Ray RM: Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol 1996;144:281–289.
81.
Combined oral contraceptives and liver cancer: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1989;43:254–259.
82.
Combined oral contraceptives and gallbladder cancer: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 1989;18:309–314.
83.
Breast cancer and depot-medroxyprogesterone acetate: a multinational study – the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Lancet 1991;338:833–838.
84.
Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB: Depot-medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995;273:799–804.
85.
Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:191–105.
86.
Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186–190.
87.
Depot-medroxyprogesterone acetate (DMPA) and risk of invasive squamous cell cervical cancer: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Contraception 1992;45:299–312.
88.
Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer: the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:182–185.
89.
D’Arcangues C: Worldwide use of intrauterine devices for contraception. Contraception 2007;75(suppl 6):52–57.
90.
The TCu 380A, TCu220C, multiload 250 and Nova T IUDs at 3, 5 and 7 years: results from three randomized multicenter trials. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction and Task Force on Safety and Efficacy of Fertility-Regulating Methods. Contraception 1990;42:141–158.
91.
Khanna J, Van Look PFA, Griffin PD (eds): Reproductive Health: A Key to a Brighter Future – Biennial Report for 1990–1991. Geneva, WHO, Special Programme of Research, Development and Research Training in Human Reproduction, 1992.
92.
Long-term reversible contraception: twelve years of experience with the TCu380A and TCu220C. Contraception 1997;56:341–352.
93.
A randomized, multicenter trial of the multiload 375 and TCu380A in parous women: three years results. UNDP/UNFPA/WHO/World Bank, Special Programme of Research, Development and Research Training in Human Reproduction: IUD Research Group. Contraception 1994;49:543–549.
94.
World Health Organization, Department of Reproductive Health and Research: Annual Technical Report 2002. Geneva, WHO, 2003.
95.
World Health Organization, Special Programme of Research in Human Reproduction: Highlights of 2005. Geneva, WHO, 2006.
96.
Hoffman KO: Postcoital contraception: experiences with ethynilestradiol/norgestrel and levonorgestrel only; in Harrison RF, Bonnar J, Thompson W (eds): Proceedings of the XI Congress on Fertility and Sterility. Lancaster, MTP Press, 1984, pp 311–316.
97.
Yuzpe AA, Turlow HJ, Ramzy I, Leyson JI: Post-coital contraception – a pilot study. J Reprod Med 1974;30:12–18.
98.
Bhattacharjee SK, Romeo J, Kononova ES, et al: Postcoital contraception with levonorgestrel during the peri-ovulatory phase of the menstrual cycle. Task Force on Post-Ovulatory Methods for Fertility Regulation. Contraception 1987;36:257–286.
99.
Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998;352:428–433.
100.
International Medical Advisory Panel, International Planned Parenthood Federation: IMAP statement on emergency contraception. IPPF Med Bull 2004;38:1–3.
101.
von Hertzen H, Van Look PF: Research on new methods of emergency contraception. Fam Plann Perspect 1996;22:62–68.
102.
Comparison of three single doses of mifepristone as emergency contraception: a randomized trial. Task Force on Post-Ovulatory Methods for Fertility Regulation. Lancet 1999;353:697–702.
103.
von Hertzen H, Piaggio G, Ding J, et al: Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 2002;360:1803–1810.
104.
Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF: Interventions for emergency contraception. Cochrane Database Syst Rev 2008;16:CD001324.
105.
Remme JH, Adam T, Becerra-Posada F, et al: Defining research to improve health systems. PLoS Med 2010;7:e1001000.
106.
Peterson HB, d’Arcangues C, Haidar J, et al: Accelerating science-driven solutions to challenges in global reproductive health: a new framework for moving forward. Obstet Gynecol 2011;117:720–726.
107.
Peterson HB, Haidar J, Merialdi M, et al: Preventing maternal and newborn deaths globally: using innovation and science to address challenges in implementing life-saving interventions. Obstet Gynecol 2011;117:720–726.
108.
Huntington D, Zaky HH, Shawky S, Fattah FA, El-Hadary E: Impact of a service provider incentive payment scheme on quality of reproductive and child-health services in Egypt. J Health Popul Nutr 2010;28:273–280.
109.
Huntington D, Banzon E, Recidoro ZD: A systems approach to improving maternal health in the Philippines. Bull World Health Organ 2012;90:104–110.
110.
Althabe F, Buekens P, Bergel E et al, Guidelines Trial Group: A behavioral intervention to improve obstetrical care. N Engl J Med 2008;358:1929–1940.
111.
Gülmezoglu AM, Langer A, Piaggio G, Lumbiganon P, Villar J, Grimshaw J: Cluster randomised trial of an active, multifaceted educational intervention based on the WHO Reproductive Health Library to improve obstetric practices. Br J Obstet Gynaecol 2007;114:16–23.
112.
Althabe F, Belizán JM, Villar J, et al, Latin American Caesarean Section Study Group: Mandatory second opinion to reduce rates of unnecessary caesarean sections in Latin America: a cluster randomised controlled trial. Lancet 2004;363:1934–1940.
113.
Fajans P, Simmons R, Ghiron L: Helping public sector health systems innovate: the strategic approach to strengthening reproductive health policies and programs. Am J Public Health 2006;96:435–440.
114.
World Health Organization: Practical guidance for scaling up health service innovations. Geneva, ExpandNet/WHO, 2009.
115.
Mohllajee AP, Curtis KM, Flanagan RG, Rinehart W, Gaffield ML, Peterson HB: Keeping up with evidence a new system for WHO’s evidence-based family planning guidance. Am J Prev Med 2005;28:483–490.
116.
Curtis KM, Peterson HB, d’Arcangues C: Keeping evidence-based recommendations up to date: the World Health Organization’s global guidance for family planning. Contraception 2009;80:323–324.
117.
World Health Organization: Medical eligibility criteria for contraceptive use, ed 4. Geneva, WHO, 2010.
118.
World Health Organization: Selected practice recommendations for contraceptive use, 2008 update. Geneva, WHO, 2008.
119.
World Health Organization: Decision-making tool for family planning clients and providers. Geneva, WHO, 2005.
120.
Johnson SL, Kim YM, Church K: Towards client-centered counseling: development and testing of the WHO Decision-Making Tool. Patient Educ Couns 2010;81:355–361.
121.
World Health Organization: Family planning: a global handbook for providers, 2007 (updated in 2008). Geneva, WHO, 2008.
122.
World Health Organization: Induced abortion: report of a Scientific Group meeting. WHO Technical Report Series 623. Geneva, WHO, 1977.
123.
Bygdeman M: The use of prostaglandins and their analogues for abortion. Clin Obstet Gynaecol 1984;11:573–584.
124.
UNDP, UNFPA, WHO, World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Post-Ovulatory Methods of Fertility Regulation: Lowering the doses of mifepristone and gemeprost for early abortion: a randomized controlled trial. Br J Obstet Gynaecol 2001;108:738–742.
125.
Tang OS, Lee SW, Ho PC: A prospective randomized study on the measured blood loss in medical termination of early pregnancy by three different misoprostol regimens after pretreatment with mifepristone. Hum Reprod 2002;17:2865–2868.
126.
von Hertzen H, Honkanen H, Piaggio G, et al: WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. 1. Efficacy. Br J Obstet Gynaecol 2003;110:808–818.
127.
Honkanen H, Piaggio G, Hertzen H, et al: WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. 2. Side effects and women’s perceptions. Br J Obstet Gynaecol 2004;111:715–725.
128.
von Hertzen H, Piaggio G, Huong NT, et al: Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomized controlled equivalence trial. Lancet 2007;369:1938–1946.
129.
von Hertzen H, Piaggio G, Wojdyla D, et al: Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 2009;24:106–112.
130.
von Hertzen H, Piaggio G, Wojdyla D, et al: Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomized controlled equivalence trial. Br J Obstet Gynaecol 2009;116:381–389.
131.
Johnson BR, Horga M, Fajans P: A strategic assessment of abortion and contraception in Romania. Reprod Health Matters 2004;12(suppl 24):184–194.
132.
Bazarragchaa T, Khishgee S, Johnson BR, Strategic Assessment Team: Applying the WHO Strategic Approach to strengthening first and second trimester abortion services in Mongolia. Reprod Health Matters 2008;16:127–134.
133.
Jackson E, Johnson BR, Gebreselassie H, Kangaude GD, Mhango C: A strategic assessment of unsafe abortion in Malawi. Reprod Health Matters 2011;19:133–143.
134.
Warriner IK, Meirik O, Hoffman M, et al: Rates of complication in first-trimester manual vacuum aspiration abortion done by doctors and mid-level providers in South Africa and Vietnam: a randomised controlled equivalence trial. Lancet 2006;368:1965–1972.
135.
Warriner IK, Wang D, Huong NT, et al: Can midlevel health-care providers administer early medical abortion as safely and effectively as doctors? A randomised controlled equivalence trial in Nepal. Lancet 2011;377:1155–1161.
136.
Sedgh G, Singh S, Shah IH, Ahman E, Henshaw SK, Bankole A: Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet 2012;379:625–632.
137.
World Health Organization: Safe abortion: technical and policy guidance for health systems, ed 2. Geneva, WHO, 2012. http://www.who.int/reproductivehealth/publications/unsafeabortion/9789241548434/en/index.html.
138.
Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;345:1455–1463.
139.
Altman D, Carroli G, Duley L, et al, Magpie Trial Collaboration Group: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877–1890.
140.
Villar J, Purwar M, Merialdi M, et al, WHO Vitamin C and Vitamin E trial group: World Health Organization multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. Br J Obstet Gynaecol 2009;116:780–788.
141.
Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M: Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007;109:168–180.
142.
von Dadelszen P, Payne B, Li J, et al, PIERS Study Group: Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the full PIERS model. Lancet 2011;377:219–227.
143.
Gülmezoglu AM, Villar J, Ngoc NT, et al, WHO Collaborative Group to Evaluate Misoprostol in the Management of the Third Stage of Labour: WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet 2001;358:689–695.
144.
Widmer M, Blum J, Hofmeyr GJ, et al: Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. Lancet 2010;375:1808–1813.
145.
Gülmezoglu AM, Lumbiganon P, Landoulsi S, et al: Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet 2012;379:1721–1727.
146.
Villar J, Ba’aqeel H, Piaggio G, et al, WHO Antenatal Care Trial Research Group: WHO antenatal care randomised trial for the evaluation of a new model of routine antenatal care. Lancet 2001;357:1551–1564.
147.
WHO study group on female genital mutilation and obstetric outcome, Banks E, Meirik O, Farley T, Akande O, Bathija H, Ali M: Female genital mutilation and obstetric outcome: WHO collaborative prospective study in six African countries. Lancet 2006;367:1835–1841.
148.
Betrán AP, Merialdi M, Lauer JA, et al: Rates of caesarean section: analysis of global, regional and national estimates. Paediatr Perinat Epidemiol 2007;21:98–113.
149.
Shah A, Fawole B, M’imunya JM, et al: Cesarean delivery outcomes from the WHO global survey on maternal and perinatal health in Africa. Int J Gynaecol Obstet 2009;107:191–197.
150.
Villar J, Valladares E, Wojdyla D, et al, WHO 2005 global survey on maternal and perinatal health research group: Caesarean delivery rates and pregnancy outcomes: the 2005 WHO global survey on maternal and perinatal health in Latin America. Lancet 2006;367:1819–1829.
151.
Lumbiganon P, Laopaiboon M, Gülmezoglu AM, et al, World Health Organization Global Survey on Maternal and Perinatal Health Research Group: Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007–08. Lancet 2010;375:490–499.
152.
Torloni MR, Daher S, Betrán AP, et al: Portrayal of caesarean section in Brazilian women’s magazines: 20 year review. Br Med J 2011;342:d276.
153.
Gibbons L, Belizan JM, Lauer JA, Betran AP, Merialdi M, Althabe F: Inequities in the use of cesarean section deliveries in the world. Am J Obstet Gynecol 2012;206:331.e1–e19.
154.
Torloni MR, Betran AP, Souza JP, et al: Classifications for cesarean section: a systematic review. PLoS One 2011;6:e14566.
155.
Rouet F, Foulongne V, Viljoen J, et al, WHO/ANRS 1289 Kesho Bora Study Group: Comparison of the generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 Easy Q v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods 2010;163:253–257.
156.
Viljoen J, Gampini S, Danaviah S, et al, WHO/ANRS 1289 Kesho Bora Study Group: Dried blood spot HIV-1 RNA quantification using open real-time systems in South Africa and Burkina Faso. J Acquir Immune Defic Syndr 2010;55:290–298.
157.
Kania D, Fao P, Valéa D, et al, WHO/ANRS 1289 Kesho Bora Study Group in Burkina Faso: Low prevalence rate of indeterminate serological human immunodeficiency virus results among pregnant women from Burkina Faso. West Afr J Clin Microbiol 2010;48:1333–1336.
158.
Kesho Bora Study Group: Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr 2010;54:533–541.
159.
Cames C, Saher A, Ayassou KA, Cournil A, Meda N, Simondon KB: Acceptability and feasibility of infant feeding options: experiences of HIV-infected mothers in the World Health Organization Kesho Bora mother-to-child transmission prevention (PMTCT) trial in Burkina Faso. Matern Child Nutr 2010;6:253–265.
160.
Kesho Bora Study Group, de Vincenzi I: Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011;11:171–180.
161.
Kesho Bora Study Group: Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora multicentre collaborative study rationale, design, and implementation challenges. Contemp Clin Trials 2011;32:74–85.
162.
Irungu E, Chersich MF, Sanon C, et al, Kesho Bora Study Group: Changes in sexual behaviour among HIV-infected women in west and east Africa in the first 24 months after delivery. AIDS 2012;26:997–1007.
163.
The Kesho Bora Study Group: Maternal HIV-1 disease progression 18–24 months post-delivery according to antiretroviral prophylaxis regimen (triple-antiretroviral prophylaxis during pregnancy and breastfeeding vs zidovudine/single-dose nevirapine prophylaxis): the Kesho Bora randomized-controlled trial. Clin Infect Dis 2012;55:449–460.
164.
World Health Organization, HIV/AIDS Programme: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach – 2010 revision. Geneva, WHO, 2010.
165.
World Health Organization: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector – progress report 2010. Geneva, WHO, 2011, pp 145–150.
166.
Deperthes BD, Meheus A, O’Reilly K, Broutet N: Maternal and congenital syphilis programmes: case studies in Bolivia, Kenya and South Africa. Bull World Health Organ 2004;82:410–416.
167.
Munkhuu B, Liabsuetrakul T, Chongsuvivatwong V, McNeil E, Janchiv R: One-stop service for antenatal syphilis screening and prevention of congenital syphilis in Ulaanbaatar, Mongolia: a cluster randomized trial. Sex Transm Dis 2009;36:714–720.
168.
Munkhuu B, Liabsuetrakul T, McNeil E, Janchiv R: Feasibility of one-stop antenatal syphilis screening in Ulaanbaatar, Mongolia: women and providers perspectives. Southeast Asian J Trop Med Public Health 2009;40:861–870.
169.
World Health Organization, Department of Reproductive Health and Research: The global elimination of congenital syphilis: rationale and strategy for action. Geneva, WHO, 2007, p 48.
170.
World Health Organization: Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy, 2009. 2012. http://www.who.int/reproductivehealth/publications/cancers/9789241503860/en/index.html.
171.
Santesso N, Schünemann H, Blumenthal P, et al, World Health Organization Steering Committee for the Recommendations on the Use of Cryotherapy for Cervical Cancer Prevention: World Health Organization Guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2012;118:97–102.
172.
World Health Organization, Department of Reproductive Health and Research: WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Geneva, WHO, 2011, p 28.
173.
World Health Organization, Department of Reproductive Health and Research and Department of Chronic Diseases and Health Promotion: Comprehensive cervical cancer control: a guide to essential practice. Geneva, WHO, 2006, p 284.
174.
Warriner IK, Jejeebhoy SJ, Shah IH: Risk taking behaviours among adolescents in developing countries: evidence from a WHO research initiative (oral presentation). Population Association of America, Annual Meeting, Detroit, 2009.
175.
Foeg M, Damgaard-Petersen F, Gormsen J, Knudsen JB, Schou G: Oral levonorgestrel-testosterone effects on spermatogenesis, hormone levels, coagulation factors and lipoproteins in normal men. Contraception 1980;21:381–391.
176.
Paulsen CA: Androgen-progestogen combinations; in Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ (eds): Male Contraception: Advances and Future Prospects. Philadelphia, Harper & Row, 1986, pp 30–303.
177.
World Health Organization, Special Programme of Research in Human reproduction: Annual Technical Report for 1996. Geneva, WHO, 1997.
178.
World Health Organization, Special Programme of Research in Human Reproduction: Annual Technical Report for 1995. Geneva, WHO, 1996.
179.
WHO Laboratory Manual for the Examination and Processing of Human Semen, ed 5. Geneva, WHO, 2010.
180.
World Health Organization: Prevention and treatment of HIV and other sexually transmitted infections among men who have sex with men and transgender people: recommendations for a public health approach. 2011. http://www.who.int/hiv/pub/guidelines/msm_guidelines2011/en/.
181.
Gruskin S, Cottingham J, Martin Hilber A, Kismodi E, Lincetto O, Roseman MJ: Using human rights to improve maternal and neonatal health: history, connections and a proposed practical approach. Bull World Health Organ 2008;86:589–593.
182.
Cottingham J, Kismodi E, Hilber AM, Lincetto O, Stahlhofer M, Gruskin S: Using human rights for sexual and reproductive health: improving legal and regulatory frameworks. Bull World Health Organ 2010;88:551–555.
183.
World Health Organization: Sexual and reproductive health and human rights: a tool for examining laws, regulations and policies. Geneva, WHO, in press.
184.
United Nations, Department of Public Information: Secretary-General, in message on International Day, says violence against women is an atrocious manifestation of continued inequality. Press release SG/SM/10225OBV/527/WOM/1524 dated 22 November 2005. http://www.un.org/News/Press/docs/2005/sgsm10225.doc.htm.
185.
Garcia-Moreno C, Heise L, Jansen HA, Ellsberg M, Watts C: Violence against women. Science 2005;310:1282–1283.
186.
Benagiano G, Carrara S, Filippi V: Social and ethical determinants of sexuality. 2. Gender-based violence. Eur J Contracept Reprod Health Care 2010;15:220–231.
187.
García-Moreno C, Watts C, Jansen HA, Ellsberg M, Heise L: Responding to violence against women: WHO’s multi-country study on women’s health and domestic violence. Health Hum Rights 2003;6:113–127.
188.
García-Moreno C, Jansen H, Ellsberg M, Heise L, Watts CH: Prevalence of intimate partner violence: findings from the WHO multi-country study on women’s health and domestic violence. Lancet 2006;368:1260–1269.
189.
Ellsberg M, Jansen HA, Heise L, Watts CH, García-Moreno C, WHO Multi-country Study on Women’s Health and Domestic Violence against Women Study Team: Intimate partner violence and women’s physical and mental health in the WHO multi-country study on women’s health and domestic violence: an observational study. Lancet 2008;371:1165–1172.
190.
Pallitto CC, García-Moreno C, Jansen HA, Heise L, Ellsberg M, Watts C, WHO Multi-Country Study on Women’s Health and Domestic Violence: Intimate partner violence, abortion and unintended pregnancy: results from the WHO multi-country study on women’s health and domestic violence. Int J Obstet Gynecol, 2012, E-pub ahead of print.
191.
Mundigo A, Indriso C (eds): Abortion in the Developing World: Findings from WHO Case Studies. New Delhi, Sage, 1998.
192.
World Health Organization, Department of Reproductive Health and Research: Annual Technical Report 2000. Geneva, WHO, 2001.
193.
World Health Organization: The World Health Report 2008 – Primary Health Care (Now More than Ever). http://www.who.int/whr/2008/en/.
194.
World Health Organization: Sexual and reproductive health core competencies in primary care: attitudes, knowledge, ethics, human rights, leadership, management, teamwork, community work, education, counselling, clinical settings, service, provision. http://www.who.int/repro-ductivehealth/publications/health_systems/9789241501002/en/.
195.
Oxman AD, Lavis JN, Fretheim A: Use of evidence in WHO recommendations. Lancet 2007;369:1883–1889.
196.
Mohllajee AP, Curtis KM, Flanagan RG, Rinehart W, Gaffield ML, Peterson HB: Keeping up with evidence a new system for WHO’s evidence-based family planning guidance. Am J Prev Med 2005;28:483–490.
197.
Peterson HB, d’Arcangues C, Haidar J, Curtis KM, Merialdi M, Gülmezoglu AM, Say L, Mbizvo M: Accelerating science-driven solutions to challenges in global reproductive health: a new framework for moving forward. Obstet Gynecol 2011;117:720–726.
198.
World Health Organization: The WHO application of ICD-10 to deaths during pregnancy, childbirth and puerperium: ICD MM. Geneva, WHO, 2012.
199.
Say L, Souza JP, Pattinson RC, WHO Working Group on Maternal Mortality and Morbidity Classifications: Maternal near miss – towards a standard tool for monitoring quality of maternal health care. Best Pract Res Clin Obstet Gynaecol 2009;23:287–296.
200.
Trends in maternal mortality: 1990–2008 – estimates developed by WHO, UNICEF, UNFPA, and the World Bank. Geneva, WHO, 2010.
201.
Trends in maternal mortality: 1990 to 2010 – WHO, UNICEF, UNFPA and the World Bank estimates. Geneva, WHO, 2012.
202.
Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF: WHO analysis of causes of maternal death: a systematic review. Lancet 2006;367:1066–1074.
203.
Beck S, Wojdyla D, Say L, et al: The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010;88:31–38.
204.
Blencowe H, Cousens S, Oestergaard MZ, et al: National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162–2172.
205.
Cousens S, Stanton C, Blencowe H, et al: National, regional and global estimates of stillbirth rates in 2009 with trends since 1995. Lancet 2011;377:1319–1330.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
